Atalanta Sosnoff Capital LLC Sells 43,573 Shares of Boston Scientific Corporation $BSX

Atalanta Sosnoff Capital LLC lowered its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 651,995 shares of the medical equipment provider's stock after selling 43,573 shares during the quarter. Boston Scientific comprises 1.2% of Atalanta Sosnoff Capital LLC's portfolio, making the stock its 28th biggest holding. Atalanta Sosnoff Capital LLC's holdings in Boston Scientific were worth $62,168,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. Renaissance Group LLC purchased a new position in Boston Scientific during the 4th quarter valued at $28,064,000. Rathbones Group PLC boosted its holdings in Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider's stock valued at $263,133,000 after acquiring an additional 477,680 shares during the period. Tounjian Advisory Partners LLC purchased a new position in Boston Scientific during the 4th quarter valued at $1,477,000. Finally, Waycross Partners LLC purchased a new position in Boston Scientific during the 4th quarter valued at $2,384,000. Institutional investors own 89.07% of the company's stock.

Analysts Set New Price Targets

BSX has been the topic of a number of research reports. Jefferies Financial Group reduced their target price on shares of Boston Scientific from $110.00 to $100.00 and set a "buy" rating on the stock in a research report on Wednesday, April 22nd. Canaccord Genuity Group lowered their target price on Boston Scientific from $71.00 to $70.00 and set a "buy" rating for the company in a report on Monday, June 1st. Daiwa Securities Group cut Boston Scientific from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 29th. Weiss Ratings cut Boston Scientific from a "hold (c)" rating to a "hold (c-)" rating in a report on Wednesday, May 13th. Finally, Mizuho lowered their target price on Boston Scientific from $115.00 to $90.00 and set an "outperform" rating for the company in a report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $85.08.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $46.83 on Friday. Boston Scientific Corporation has a one year low of $45.99 and a one year high of $109.50. The company has a market cap of $69.60 billion, a price-to-earnings ratio of 19.59, a PEG ratio of 0.89 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The business's 50 day moving average price is $56.37 and its 200 day moving average price is $74.95.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter last year, the business posted $0.75 earnings per share. The firm's revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation NYSE: BSX - Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Insiders Place Their Bets

In related news, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company's stock, valued at $99,987.30. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David C. Habiger bought 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 9,800 shares of company stock valued at $554,012 over the last quarter. 0.34% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.